Safety Study of Imexon Treatment of Patients With Metastatic or Disseminated Malignancy
Status:
Completed
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
AMP-011 is a Phase 1 study designed to extend the understanding of the toxicity and
pharmacology of imexon by investigating a schedule of daily treatment for 5 days every three
weeks. The objective of the study is to determine the maximally tolerated dose, the
pharmacokinetics, and the toxicity of the drug on the designated schedule.